Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.32 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15927345 | 1.00 | ALDH1A1 (0.34) | ALDH1A1KDM4EKMT2AHIF1ACYP2C19 | |
| SCHEMBL20031318 | 0.85 | GABRA1 (0.31) | ALDH1A1HIF1ACYP2C19GABRA1GABRB2 | |
| SCHEMBL13209255 | 0.84 | GABRA1 (0.40) | ALDH1A1KDM4EKMT2AHIF1AGABRA1 | |
| SCHEMBL23489771 | 0.83 | PDE2A (0.39) | ALDH1A1GABRA1GABRB2PDE2AL3MBTL1 | |
| SCHEMBL31085176 | 0.83 | PDE2A (0.39) | ALDH1A1GABRA1GABRB2PDE2AL3MBTL1 | |
| SCHEMBL17679292 | 0.80 | PDE2A (0.38) | ALDH1A1KDM4EKMT2AHIF1ACYP2C19 | |
| SCHEMBL17679293 | 0.80 | PDE2A (0.38) | ALDH1A1KDM4EKMT2AHIF1ACYP2C19 | |
| SCHEMBL17679296 | 0.79 | KDM4E (0.31) | ALDH1A1KDM4EKMT2A | |
| SCHEMBL7464555 | 0.79 | HIF1A (0.34) | ALDH1A1KDM4EKMT2AHIF1ACYP2C19 | |
| SCHEMBL17679295 | 0.79 | KDM4E (0.31) | ALDH1A1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027257-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | KANION USA INC. | 2023-01-26 | — | — | US | disclosed |
| US-11248013-B2 | Tricyclic inhibitors of poly(ADP-ribose)polymerase | RAKOVINA THERAPEUTICS INC. (CA) | 2022-02-15 | — | — | US | disclosed |
| US-20200299315-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | RAKOVINA THERAPEUTICS INC. (CA) | 2020-09-24 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-20180094010-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | NEWGEN THERAPEUTICS INC (US) | 2018-04-05 | — | — | US | disclosed |
| US-20180094010-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | NEWGEN THERAPEUTICS INC (US) | 2018-04-05 | — | — | US | disclosed |
| US-20170057984-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | NEWGEN THERAPEUTICS INC (US) | 2017-03-02 | — | — | US | disclosed |
| US-20170057984-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | NEWGEN THERAPEUTICS INC (US) | 2017-03-02 | — | — | US | disclosed |
| US-20160102073-A1 | 2-HYDROXYMETHYL-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-04-14 | — | — | US | disclosed |
| US-20140221314-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | NEWGEN THERAPEUTICS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221314-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP11 | ALDH1A1 1069/4885KDM4E 2241/4885KMT2A 813/4885 |
| US-20230027257-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP11 | ALDH1A1 1069/4885KDM4E 2241/4885KMT2A 813/4885 |
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | ALDH1A1 1320/4885KDM4E 1648/4885KMT2A 1471/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | ALDH1A1 1320/4885KDM4E 1648/4885KMT2A 1471/4885 |
| US-20170057984-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP11 | ALDH1A1 1069/4885KDM4E 2241/4885KMT2A 813/4885 |
| US-20180094010-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP11 | ALDH1A1 1069/4885KDM4E 2241/4885KMT2A 813/4885 |
| US-11248013-B2 | Tricyclic inhibitors of poly(ADP-ribose)polymerase | PARP1, PARP2, PARP11 | ALDH1A1 1069/4885KDM4E 2241/4885KMT2A 813/4885 |
| US-20200299315-A1 | TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP11 | ALDH1A1 1282/4885KDM4E 2303/4885KMT2A 784/4885 |
| US-20160102073-A1 | 2-HYDROXYMETHYL-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, CRHR2 | ALDH1A1 1438/4885KDM4E 498/4885KMT2A 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.